Why the success of your HTA will rely on real world evidence
pharmaphorum
FEBRUARY 11, 2016
The first in a trilogy of webinars focussed on the topic; Unlocking the value; the economic equation and part of the IMS Health Practical Insights series. While it remains the gold standard, the feasibility of large scale randomised clinical trials within a pipeline that is ever more focused on niche and personalised medicines is decreasing – particularly in the fields of rare diseases and oncology.
52 
Let's personalize your content